Friday, 20 Oct 2017

You are here

RheumNow Week in Review – 15 July 2016

Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.

  1. FDA Approves Xiidra (Lifitegrast), an LFA-1 agonits for Dry Eyes. 
  2. FDA Arthritis Advisory Committee Votes 26-0 to Recommend Approval of Adalimumab Biosimilar (Amgens ABP-501).  
  3. Sandoz Etanercept Biosimilar (GP-2015) Unanimously (20-0) Voted for Approval by FDA Arthritis Advisory Committee.  
  4.  FDA Says Cryotherapy, not approved, lacks evidence and poses risks.  http://rheumnow.com/content/fda-says-cryotherapy-lacks-evidence-poses-risks
  5. Vagal Stimulation Decreases Proinflammatory Cytokine Production and Rheumatoid Disease Activity.  
  6. Lupus panniculitis appears as indurated nodules/plaques with lipoatrophy, usually over the proximal extremities & trunk. Important to get a deep Biopsy.  Usual treatments include hydroxychloroquine, steroid, dapsone, others reviewed. https://t.co/CJ5uJHxtcF
  7. In 428 SpA pts, BMI (obesity) had no effect on ASDAS. BMI weakly correlates with CRP, other PRO's. https://t.co/FcTfEicYpN
  8. Small study of Bactrim in GPA (Wegeners) shows 25% relapse w/ continued Rx vs 45% relapse with Bactrim withdrawal. https://t.co/IQksnzI5mk
  9. German RABBIT registry study >13K pts shows an increased risk of lower GI perforations with Actemra (2.7/1000PY), with a four fold higher risk than other therapys.  Nearly 25% of such patients died. https://t.co/u9A4TRFMso
  10. Prevalence of gout increasing in EU from 1.7% to 2.5%; in the US to 4%. Gout is becoming epidemic. https://t.co/zSSRbTId73
  11. 100k German RA compared to 500k controls: RA patients were vaccinated more; but more pneumonia hospitalizations were seen in regions with low or no vaccination https://t.co/HxOIIOf0rP
  12. 234 RA patients treated with Rituxan for a mean of 28 mos. Showed a retention rate of 57%. Discontinuatoins were associated with higher age, greater swollen joint counts, lack of concomitant MTX use.  https://t.co/QRLR9mgP84

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review - 20 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses presentations from APLAR 2017 in Dubai, Catastrophic APS, safety of low-dose prednisone, frequency of psoriatic arthritis and a new drug for PsA and a hepatitis A outbreak in San Diego.

13 October 2017 The RheumNow Week in Review

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses a novel antiviral drug or the use of stem cell therapy for scleroderma, rituximab in HSP, when to withdraw NSAIDS in RA, and congrats to PAs and NPs!

The Big Need - NPs and PAs

Despite being one of the most satisfying of medical subspecialties, the number of U.S. rheumatologists is about to sharply decline.  These data were presented at the 2016 ACR meeting, where it was shown that the estimated total number of U.S. rheumatologists in in 2015 was 4,933 and is projected decrease to 3,645 by 2025. During this declining clinical supply, there will be a 138% increase in demand from 6,155 to 8,184 by 2030.

Arthritis Burden over $303 Billion Annually in U.S.

Arthritis of all types in the U.S. carried an economic burden of $303.5 billion in 2013, nearly 1% of the gross domestic product that year, according to a CDC analysis.

The RheumNow Week in Review - 6 October 2017

The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.